DESTINY PHARMA PLC The potential utility of XF-73 in this indication is due to the long-recognised association between the development of OM and changes in the oral microbiome. The unique antimicrobial properties of XF-73 have already been demonstrated in Phase 2 clinical trials. As well as having fast-acting antimicrobial activity and a novel mechanism of action, XF-73 has an excellent safety profile and a lack of systemic exposure which means that it is ideally suited for development as an innovative oral formulation to reduce the severity of OM.
Inflammation of the mucosa (mucositis) is considered one of the most serious non-hematological complications of cancer treatment and a common dose-limiting complication of high-dose radiotherapy and chemotherapy in cancer and bone marrow transplant patients of all ages. Globally, more than two million cancer patients suffer from this condition each year. The global OM market was estimated at
Despite its frequency and devastating impact, there are few approved preventive or treatment options available to help patients suffering from OM. Professor
Contact:
CEO
CFO
T: +44 (0)1273 704 440
E: pressoffice@destinypharma.com
Mary Clark
T: +44 (0) 203 922 0891
E: DestinyPharma@optimumcomms.com
finnCap Ltd
Nominated Advisor and Broker
Corporate Finance
ECM
T: +44 (0) 207 220 0500
T: +49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the company, please visit www.destinypharma.com
About Oral Mucositis
Inflammation of the mucosa (mucositis) is a common dose limiting complication of high dose radiotherapy and chemotherapy in cancer patients of all ages. It can affect the mucosa of the entire gastrointestinal system from oral cavity to anus. Oral Mucositis ('OM') is common and occurs in 40-70% of patients undergoing high dose radiotherapy and chemotherapy. OM is responsible for reduction or cessation of cancer treatment in 35% of patients, impacting the clinical outcome interventions (Sonis, 2014).
Despite its frequency and impact there are few approved preventive or treatment options. Existing treatments are unsatisfactory, consisting of mouthwashes and sprays containing anaesthetics, steroids, protective hydrogels and/or local pain management.
The target market for XF-73OM is estimated at over 2m OM patients/year. The global OM market was estimated at
Smaller, targeted indications include BMT patients where severe OM is reported in >80% of patients. There are >2,000 BMTs every year in the
OM patients require specialised care such as parenteral nutrition, fluid replacement and anti-infective treatment. A single point increase in peak mucositis scores in hematopoietic stem cell transplant patients is associated with one additional day of fever, a 2-fold increase in risk of significant infection, 2.7 additional days of total parenteral nutrition, 2.6 additional days of injectable narcotic therapy, 2.6 additional days in hospital and a 3.9 fold increase in 100-day mortality risk.
The healthcare cost of OM is substantial. In the US, the estimated cost of hospitalisation was
(C) 2022 Electronic News Publishing, source
